The Wake Forest Institute for Regenerative Medicine (WFIRM) is at the forefront of regenerative medicine, focusing on the development of innovative therapies that aim to heal rather than merely treat diseases. The institute has achieved significant milestones, including being the first globally to successfully implant laboratory-grown organs into humans. WFIRM's interdisciplinary team is currently working on engineering over 40 different types of replacement tissues and organs, utilizing advanced techniques in tissue engineering and cell therapies. Their research spans various applications, including skin, bladders, kidneys, and more, demonstrating a comprehensive approach to regenerative medicine that encompasses flat structures, tubular tissues, hollow organs, and solid organs.

In addition to organ engineering, WFIRM is actively engaged in cutting-edge research initiatives that leverage breakthrough technologies such as bioprinting, gene editing, and nanotechnology. The institute collaborates with over 400 global entities, including academic institutions and industry partners, to accelerate the translation of scientific discoveries into clinical applications. Notably, WFIRM is also involved in military-focused programs and projects aimed at developing mini-organs for drug testing, showcasing its commitment to addressing urgent health needs. Through its robust infrastructure, including a clinical manufacturing center, WFIRM is dedicated to expediting the availability of regenerative therapies to patients, positioning itself as a leader in the evolution of medical treatments.

United States

The Wake Forest Institute for Regenerative Medicine is working to grow tissues and organs and develop healing cell therapies for more than 30 different areas of the body, from kidney and trachea to cartilage and lung.

Wake Forest Institute for Regenerative Medicine

Company Details